This Program Project "Hormonal Control of Calcium Metabolism" brings together a group of highly productive investigators who work closely together, as they have for years, supported by the project and stimulated by the environment of the Endocrine Unit. Powerful research tools feature the approaches of chemical and molecular biology and a number of carefully designed genetically modified animals to evaluate bone and renal cell biology as well as mineral metabolism. Exciting medical translational applications have already been initiated from this work. Project I, "Mechanisms of action of PTH ligands on the PTHR1 and implications in vivo" (Gardella PI), has led to the development of a new therapy for hypoparathyroidism (in collaboration with NIGH BrIDGs program), exciting new directions in peptide design including signal selective compounds and newer types of long-acting PTH molecules, as well as peptidomimetics (in collaboration with NlH's small molecule screening program MLPCN). Project II, "PTH actions on cells of the osteoblast lineage" (Kronenberg PI), and Project III, "Role of PTH/PTHrP receptor and RANKL in osteoblastic cells in vivo" (Divieti Pajevic PI), are independent but closely related projects that explore the cellular responses in bone to PTH employing powerful new techniques developed by the investigators to study the proliferation and differentiation of cells of the osteoblast lineage in vivo, roles of histone deacetylases in the cellular responses to bone anabolic actions of PTH and results of deletion of the PTH receptor in osteoblastic cells at varying stages of differentiation. This effort is fundamental to understanding how to improve the therapeutic response to PTH in fracture healing and in patients with osteoporosis. Project IV, "PTH actions on renal target cells in the regulation of renal phosphate excretion" (Jueppner PI), examines key features of signal selectivity in PTH action, especially on renal phosphate transport and the desensitization of the cAMP/PKA pathway with chronic PTH exposure with the ensuing compensation by the IP3/PKC pathway, emphasizing the potential role of PTH ligands with enhanced IP3/PKC signaling in improving treatment in chronic renal disease (CKD).
Great promise for closing gaps in knowledge about molecular mechanisms of parathyroid hormone action (PTH), PTH roles in bone and renal cell biology and calcium and phosphate homeostasis, and several important potential translational applications in osteoporosis, fracture healing and chronic renal disease.
|Bi, Ruiye; Fan, Yi; Lauter, Kelly et al. (2016) Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog. J Bone Miner Res 31:975-84|
|Stevenson, Hilary P; Lin, Guowu; Barnes, Christopher O et al. (2016) Transmission electron microscopy for the evaluation and optimization of crystal growth. Acta Crystallogr D Struct Biol 72:603-15|
|Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107|
|Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2016) Sclerostin Antibody Administration Converts Bone Lining Cells into Active Osteoblasts. J Bone Miner Res :|
|Wein, Marc N; Liang, Yanke; Goransson, Olga et al. (2016) SIKs control osteocyte responses to parathyroid hormone. Nat Commun 7:13176|
|Eda, Homare; Santo, Loredana; Wein, Marc N et al. (2016) Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res 31:1225-34|
|Sinha, Partha; Aarnisalo, Piia; Chubb, Rhiannon et al. (2016) Loss of GsÎ± in the Postnatal Skeleton Leads to Low Bone Mass and a Blunted Response to Anabolic Parathyroid Hormone Therapy. J Biol Chem 291:1631-42|
|Tenhola, Sirpa; Voutilainen, Raimo; Reyes, Monica et al. (2016) Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation. Eur J Endocrinol 175:211-8|
|Cheloha, Ross W; Watanabe, Tomoyuki; Dean, Thomas et al. (2016) Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist. ACS Chem Biol 11:2752-2762|
|Hattersley, Gary; Dean, Thomas; Corbin, Braden A et al. (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141-9|
Showing the most recent 10 out of 195 publications